CPL500036 - low dose + CPL500036 - high dose + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
May 19, 2021 → Jun 19, 2024
NCT ID
NCT05278156About CPL500036 - low dose + CPL500036 - high dose + Placebo
CPL500036 - low dose + CPL500036 - high dose + Placebo is a phase 2 stage product being developed by Celon Pharma for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT05278156. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05297201 | Phase 2 | Completed |
| NCT05278156 | Phase 2 | Completed |
Competing Products
20 competing products in Schizophrenia